Breath of Innovation®
Verona Pharma is developing life enhancing treatments for chronic respiratory diseases.
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023
We’re a clinical‑stage biopharmaceutical company focused on developing and commercializing innovative prescription medicines.
We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.
The unmet need
→COPD
Cystic Fibrosis
Asthma
Chronic Obstructive Pulmonary Disease is a progressive respiratory disease without a cure.
The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the Global Initiative for Chronic Obstructive Lung Disease.
Find out moreLatest news
Latest Film
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD
Verona Pharma
Investor Information
© Verona Pharma plc 2023. All rights reserved
Ensifentrine (RPL554): Mechanism of action
Ensifentrine is a Phase 3, first-in-class candidate for the maintenance treatment of COPD.